Cholesterol paradox in atrial fibrillation: is it solved in lipid-lowering drugs users?

Back

Open Access

Cholesterol paradox in atrial fibrillation: is it solved in lipid-lowering drugs users?

Session: Young Investigator Award - Primary Care & Risk Factor Management

Topic: Lipids

Speaker: Mr B. Bartos (Olsztyn, PL)

Event: ESC Preventive Cardiology 2024

Congress Presentation

Add to my library

About the speaker

Mr Bartlomiej Bartos

SGMK Copernicus University, Olsztyn (Poland)

0 follower

4 more presentations in this session

Early insulin resistance in low-risk subjects with normal glycemia is associated with subclinical atherosclerosis

Speaker: Doctor J. Iglesies-Grau (Montreal, CA)

Development, validation and prospective clinical implementation of a machine learning algorithm for incident cardio-renal-metabolic diseases and cardiovascular death: the OPTIMISE study.

Speaker: Doctor R. Nadarajah (Leeds, GB)

Comparative effectiveness of non-pharmacological interventions on metabolic syndrome and its components: a systematic review and network meta-analysis

Speaker: Ms B. Chan (Hong Kong, HK)

Higher inflammatory cytokines in long-covid with cardiovascular symptoms after acute severe COVID-19? A two-year, pre-vaccine, longitudinal, exploratory, nested cohort.

Speaker: Doctor C. Luz Goulart (Manaus, BR)

Access the full session

Young Investigator Award - Primary Care & Risk Factor Management

Speakers: Mr B. Bartos, Doctor J. Iglesies-Grau, Doctor R. Nadarajah, Ms B. Chan, Doctor C. Luz Goulart

Access

About the event

ESC Preventive Cardiology 2024

25 April - 27 April 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources